---
title: "JINGXIN released its 2024 annual performance, with a net profit attributable to the parent company of 712 million yuan, an increase of 15.04%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/234208324.md"
description: "JINGXIN announced its 2024 annual performance, with operating revenue of 4.159 billion yuan, a year-on-year increase of 3.99%; net profit attributable to the parent company of 712 million yuan, a year-on-year increase of 15.04%. The net profit excluding non-recurring gains and losses was 647 million yuan, a year-on-year increase of 21.38%. The basic earnings per share were 0.83 yuan. The company plans to distribute a cash dividend of 3.5 yuan (including tax) for every 10 shares to all shareholders"
datetime: "2025-04-02T11:11:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/234208324.md)
  - [en](https://longbridge.com/en/news/234208324.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/234208324.md)
generator: "portal-rs"
---

# JINGXIN released its 2024 annual performance, with a net profit attributable to the parent company of 712 million yuan, an increase of 15.04%

According to the Zhitong Finance APP, JINGXIN (002020.SZ) released its annual report for 2024, reporting an operating income of 4.159 billion yuan, a year-on-year increase of 3.99%. The net profit attributable to shareholders of the listed company was 712 million yuan, a year-on-year increase of 15.04%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 647 million yuan, a year-on-year increase of 21.38%. The basic earnings per share were 0.83 yuan.

The company achieved an operating income of 4.159 billion yuan for the year, a year-on-year increase of 3.99%; among which, the revenue from finished drugs was 2.522 billion yuan, a year-on-year increase of 8.42%; the revenue from raw materials was 876 million yuan, a year-on-year decrease of 8.37%; and the revenue from medical devices was 687 million yuan, a year-on-year increase of 7.84%, maintaining steady growth in its main business.

In addition, it plans to distribute a cash dividend of 3.5 yuan (including tax) for every 10 shares to all shareholders

### Related Stocks

- [002020.CN](https://longbridge.com/en/quote/002020.CN.md)

## Related News & Research

- [ETF Savings Plans Boom in Switzerland – But Not Because of AI](https://longbridge.com/en/news/296473012.md)
- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [SALT_B: Technical advances and new partnerships drive scale-up despite lower sales and EBIT](https://longbridge.com/en/news/296575303.md)
- [ANALYSIS-War-hit European markets are far from down and out](https://longbridge.com/en/news/296565595.md)
- [Bera sells ISK 1 billion six-month commercial paper at 8.5%](https://longbridge.com/en/news/296640776.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**